Powerful partnerships help drive our research for the greater good

The Institute for Glycomics has a broad portfolio of technologies and services available to industry, investors and academic organisations. It has a management framework and expert personnel in place to meet industry demands and has successfully co-developed products using its translational capability and specialised facilities from concept to market.

For Industry

The Institute for Glycomics has a portfolio of discovery to Phase 1 technologies and novel technology platforms available for licensing and co-development. It has successfully co-developed several of its drug and vaccine assets from preclinical stage to Phase 2 human clinical trials through industry partnerships.

For investors

The Institute has a suite of technology packages available for immediate investment. The Institute is experienced in negotiating and managing a range of investment types.

Technologies available

Novel Therapeutics for hand, foot & Mouth disease

Find out more

Novel Therapeutics for Parainfluenza

Find out more

Disruptive Peptide Anti-Cancer Drug Candidates

Find out more

Synthetic Heparin Mimetics

Find out more

Success stories

World’s largest commercial glycan array launched

The Institute for Glycomics has partnered with Dextra Laboratories to launch the world’s largest commercial glycan array and bioanalytical service offering.

Find out more

Ross River virus battle breakthrough

Research conducted by Griffith and Paradigm Biopharmaceuticals has uncovered a potential new treatment in the battle against alphavirus infections.

Find out more

Strep A vaccine partnership raises hope

The Institute for Glycomics has partnered with Dextra Laboratories to launch the world’s largest commercial glycan array and bioanalytical service offering.

Find out more

Want to know more?

Get in touch with the Institute for Glycomics